Deha Onar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deha Onar has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Burçin Çolak
Department of Psychiatry, Faculty of Medicine, Ankara University, Ankara, Turkey
2 shared publications - Jamal Hasanli
Department of Psychiatry, Başkent University, Fevzi çakmak Caddesi 10. Street 38/9 Bahçelievler, Çankaya, Ankara, 06490, Turkey.
2 shared publications - Ali Özgür Karaduğan
Sultanbeyli Devlet Hastanesi, Kadın Doğum Kliniği
1 shared publication - Ateş Karateke
İstanbul Medeniyet University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey
1 shared publication - Ayhan Çeli̇k
Fatih Sultan Mehmet Eğitim Ve Araştırma Hastanesi, Perinatoloji Kliniği
1 shared publication Ayşe Handenur Bayraktar Özdemir
1 shared publication
Latest Publications
- 12 August 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 202, 74-86
The effect of tDCS on emotion-related risk-taking behavior and delay discounting in adults with ADHD
- 12 August 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 202, 74-86
The effect of tDCS on emotion-related risk-taking behavior and delay discounting in adults with ADHD
- 1 March 2024
- Published by Taylor & Francis in International Journal of Transgender Health
- Vol. 26 (3) , 795-804
Addressing fertility in gender-affirming care and its mental health implications: A cross-sectional study from Turkey
Transgender and non-binary (TNB) people may seek gender-affirming treatments and these treatments have well-known effects on fertility. The goal of this study was to identify TNB people’s desire for parenthood, perspectives on fertility preservation, and how possible involuntary childlessness in the future might negatively impact mental health. We conducted a cross-sectional questionnaire study. Participants self-reported their demographics and perspectives on parenthood and fertility preservation. In addition, they filled out scales for conceptual future parent grief (CFPG), perceived social support, perceived discrimination, satisfaction with life and depressive symptoms. A total of 67 participants were included in the study. 58.2% wanted to have children and among them 56.4% preferred genetic parenthood. Of the participants using gender-affirming treatments, 35.1% were not informed about the adverse effects on fertility. 40.3% would utilize fertility preservation if given the opportunity. Analyses suggest that CFPG accounts for 3% of the variation in depressive symptoms. Addressing fertility and CFPG might be important for promoting the psychological well-being of TNB people. This study also highlights the need for revisiting fertility related legal and healthcare aspects of gender affirmation in Turkey.
- 1 March 2024
- Published by Taylor & Francis in International Journal of Transgender Health
- Vol. 26 (3) , 795-804
Addressing fertility in gender-affirming care and its mental health implications: A cross-sectional study from Turkey
Transgender and non-binary (TNB) people may seek gender-affirming treatments and these treatments have well-known effects on fertility. The goal of this study was to identify TNB people’s desire for parenthood, perspectives on fertility preservation, and how possible involuntary childlessness in the future might negatively impact mental health. We conducted a cross-sectional questionnaire study. Participants self-reported their demographics and perspectives on parenthood and fertility preservation. In addition, they filled out scales for conceptual future parent grief (CFPG), perceived social support, perceived discrimination, satisfaction with life and depressive symptoms. A total of 67 participants were included in the study. 58.2% wanted to have children and among them 56.4% preferred genetic parenthood. Of the participants using gender-affirming treatments, 35.1% were not informed about the adverse effects on fertility. 40.3% would utilize fertility preservation if given the opportunity. Analyses suggest that CFPG accounts for 3% of the variation in depressive symptoms. Addressing fertility and CFPG might be important for promoting the psychological well-being of TNB people. This study also highlights the need for revisiting fertility related legal and healthcare aspects of gender affirmation in Turkey.
- Open Access
- 31 August 2022
- Published by Mersin Universitesi Saglik Bilimleri Dergisi in Mersin Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 15 (2) , 328-336
Sezaryen doğumda spinal anestezi sırasında profilaktik efedrin uygulamasının maternal ve fetal Doppler parametrelerine etkisi
Amaç: Bu çalışmanın amacı, spinal anestezi uygulanan elektif sezaryen yapılan hastalarda efedrinin maternal ve fetal kan akımı üzerindeki etkilerini Doppler ultrasonografi ölçümleri ile değerlendirmektir. Yöntem: Bu prospektif çift kör randomize çalışma elektif sezaryen uygulanan ve spinal anestezi için herhangi bir kontrendikasyonu olmayan kırk gebe kadın üzerinde yürütülmüştür. Çalışmaya alınan denekler efedrin alan grup (n=20) ve efedrin almayan kontrol grubu (n=20) diye 2 gruba ayrıldı. Her iki gruptaki gebelerin spinal anestezi öncesinde ve sonrasında her bir kadın için uterin arter ve fetal umbilikal arter tepe sistolik hız (S), diyasitol sonu hız (D), S/D oranı, rezistivite indeksi (RI) ve pulsatilite indeksi (PI) gibi Doppler ölçümleri kaydedildi. Bulgular: İki grup yaş, vücut kitle indeksi, gebelik yaşı ve sezaryen endikasyonu açısından eşleştirildi. Spinal anestezi öncesi (herhangi bir işlem uygulamadan önce) kontrol grubu ve efedrin grubu arasında ultrasonografik Doppler ölçüm değerleri arasında istatiksel olarak anlamlı bir fark yoktu. Efedrin grubunda diyastolik kan basıncında istatistiksel olarak anlamlı bir düşüş vardı (p0.05). Sonuç: Gebelerde spinal anestezi sırasında profilaktik efedrin uygulaması, maternal uterin arterdeki S/D artışının önüne geçerek uteroplasental perfüzyonda meydana gelebilecek engelleyebilir ve fetüsü olası hipoksi ve asidozdan koruyabilir.
- 31 August 2022
- Published by Mersin Universitesi Saglik Bilimleri Dergisi in Mersin Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 15 (2) , 328-336
Open AccessSezaryen doğumda spinal anestezi sırasında profilaktik efedrin uygulamasının maternal ve fetal Doppler parametrelerine etkisi
Amaç: Bu çalışmanın amacı, spinal anestezi uygulanan elektif sezaryen yapılan hastalarda efedrinin maternal ve fetal kan akımı üzerindeki etkilerini Doppler ultrasonografi ölçümleri ile değerlendirmektir. Yöntem: Bu prospektif çift kör randomize çalışma elektif sezaryen uygulanan ve spinal anestezi için herhangi bir kontrendikasyonu olmayan kırk gebe kadın üzerinde yürütülmüştür. Çalışmaya alınan denekler efedrin alan grup (n=20) ve efedrin almayan kontrol grubu (n=20) diye 2 gruba ayrıldı. Her iki gruptaki gebelerin spinal anestezi öncesinde ve sonrasında her bir kadın için uterin arter ve fetal umbilikal arter tepe sistolik hız (S), diyasitol sonu hız (D), S/D oranı, rezistivite indeksi (RI) ve pulsatilite indeksi (PI) gibi Doppler ölçümleri kaydedildi. Bulgular: İki grup yaş, vücut kitle indeksi, gebelik yaşı ve sezaryen endikasyonu açısından eşleştirildi. Spinal anestezi öncesi (herhangi bir işlem uygulamadan önce) kontrol grubu ve efedrin grubu arasında ultrasonografik Doppler ölçüm değerleri arasında istatiksel olarak anlamlı bir fark yoktu. Efedrin grubunda diyastolik kan basıncında istatistiksel olarak anlamlı bir düşüş vardı (p0.05). Sonuç: Gebelerde spinal anestezi sırasında profilaktik efedrin uygulaması, maternal uterin arterdeki S/D artışının önüne geçerek uteroplasental perfüzyonda meydana gelebilecek engelleyebilir ve fetüsü olası hipoksi ve asidozdan koruyabilir.
- 20 May 2022
- Published by Wiley in Psych Journal
- Vol. 11 (4) , 550-559
Factors associated with progression of depression, anxiety, and stress‐related symptoms in outpatients and inpatients with COVID‐19: A longitudinal study
It is known that there is an increase in the frequency of psychiatric disturbances in the acute and post‐illness phase of coronavirus disease (COVID‐19). Comorbid psychiatric symptoms complicate the management of patients and negatively affect the prognosis, but there is no clear evidence of their progress. We aimed to determine psychiatric comorbidity in inpatients and outpatients with COVID‐19 and recognize the factors that predict psychiatric comorbidity. For this purpose, we evaluated patients on the first admission and after 4 weeks. We investigated psychiatric symptoms in outpatients (n = 106) and inpatients (n = 128) diagnosed with COVID‐19. In the first 7 days after diagnosis (first phase), sociodemographic and clinic data were collected, a symptom checklist was constructed, and the Hospital Anxiety and Depression Scale (HADS) and the Severity of Acute Stress Symptoms Scale (SASSS) were applied. After 30–35 days following the diagnosis, the SASSS and the HADS were repeated. In the first phase, the frequency of depression and anxiety were 55% and 20% in inpatients, and 39% and 18% in outpatients, respectively. In the second phase, depression scores are significantly decreased in both groups whereas anxiety scores were decreased only in inpatients. The frequencies of patients reporting sleep and attention problems, irritability, and suicide ideas decreased after 1 month. Patients with loss of smell and taste exhibit higher anxiety and depression scores in both stages. Our results revealed that the rate of psychiatric symptoms in COVID‐19 patients improves within 1 month. Inpatients have a more significant decrease in both depression and anxiety frequency than do outpatients. The main factor affecting anxiety and depression was the treatment modality. Considering that all patients who were hospitalized were discharged at the end of the first month, this difference may be due to the elimination of the stress caused by hospitalization.
- 20 May 2022
- Published by Wiley in Psych Journal
- Vol. 11 (4) , 550-559
Factors associated with progression of depression, anxiety, and stress‐related symptoms in outpatients and inpatients with COVID‐19: A longitudinal study
It is known that there is an increase in the frequency of psychiatric disturbances in the acute and post‐illness phase of coronavirus disease (COVID‐19). Comorbid psychiatric symptoms complicate the management of patients and negatively affect the prognosis, but there is no clear evidence of their progress. We aimed to determine psychiatric comorbidity in inpatients and outpatients with COVID‐19 and recognize the factors that predict psychiatric comorbidity. For this purpose, we evaluated patients on the first admission and after 4 weeks. We investigated psychiatric symptoms in outpatients (n = 106) and inpatients (n = 128) diagnosed with COVID‐19. In the first 7 days after diagnosis (first phase), sociodemographic and clinic data were collected, a symptom checklist was constructed, and the Hospital Anxiety and Depression Scale (HADS) and the Severity of Acute Stress Symptoms Scale (SASSS) were applied. After 30–35 days following the diagnosis, the SASSS and the HADS were repeated. In the first phase, the frequency of depression and anxiety were 55% and 20% in inpatients, and 39% and 18% in outpatients, respectively. In the second phase, depression scores are significantly decreased in both groups whereas anxiety scores were decreased only in inpatients. The frequencies of patients reporting sleep and attention problems, irritability, and suicide ideas decreased after 1 month. Patients with loss of smell and taste exhibit higher anxiety and depression scores in both stages. Our results revealed that the rate of psychiatric symptoms in COVID‐19 patients improves within 1 month. Inpatients have a more significant decrease in both depression and anxiety frequency than do outpatients. The main factor affecting anxiety and depression was the treatment modality. Considering that all patients who were hospitalized were discharged at the end of the first month, this difference may be due to the elimination of the stress caused by hospitalization.